Poukalov Konstantin
SEC-identified person · CIK 1678736 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Arya Sciences Acquisition Corp IV ARYD | Chief Business Officer | filed 2021–2024 |
| Lyra Therapeutics, Inc. LYRA | Director | filed 2020–2024 |
| Lianbio LIAN | Director | filed 2021–2024 |
| Arya Sciences Acquisition Corp V ARYE | Chief Business Officer | filed 2021–2021 |
| Landos Biopharma, Inc. LABP | Director | filed 2021–2021 |
| Nautilus Biotechnology, Inc. [NAUT] | Chief Business Officer | filed 2020–2020 |
| Cerevel Therapeutics Holdings, Inc. CERF | Chief Business Officer | filed 2020–2020 |
| Kadmon Holdings, LLC kdmn | Executive Vice President, CFO | filed 2016–2017 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.